tiprankstipranks
Scinai Immunotherapeutics Licenses Global Rights
Company Announcements

Scinai Immunotherapeutics Licenses Global Rights

Scinai Immunotherapeutics (SCNI) has released an update.

Don't Miss our Black Friday Offers:

Scinai Immunotherapeutics Ltd. has struck a significant deal, granting exclusive global rights to their patented immunotherapy technologies and related know-how to an unnamed U.S. company. The agreement includes an immediate license fee, contingent milestone payments, and royalties on future net sales. This move marks a strategic step for Scinai in the development and commercialization of its licensed products.

For further insights into SCNI stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskScinai Immunotherapeutics Gains Shareholder Confidence
TipRanks Auto-Generated NewsdeskScinai Immunotherapeutics to Hold Annual Shareholder Meeting
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App